- Home
- RVT vs ELVN Comparison
RVT vs ELVN Comparison
Compare RVT & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RVT | ELVN |
|---|---|---|
| Founded | 1986 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.2B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | RVT | ELVN |
|---|---|---|
| Price | $18.23 | $50.99 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $43.40 |
| AVG Volume (30 Days) | 412.7K | ★ 2.4M |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | ★ 7.32% | N/A |
| EPS Growth | N/A | ★ 3.17 |
| EPS | ★ 2.95 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $6.17 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.78 | $14.79 |
| 52 Week High | $18.88 | $52.39 |
Technical Indicators
Market Signals| Indicator | RVT | ELVN |
|---|---|---|
| Relative Strength Index (RSI) | 50.40 | 64.00 |
| Support Level | $18.06 | $25.63 |
| Resistance Level | $18.69 | $52.39 |
| Average True Range (ATR) | 0.29 | 2.66 |
| MACD | -0.01 | 0.18 |
| Stochastic Oscillator | 54.50 | 82.11 |
Price Performance
Historical ComparisonAbout RVT Royce Value Trust Inc.
Royce Small-Cap Trust Inc is a diversified closed-end investment company that invests in equity securities of small-cap companies. The company portfolio includes sectors such as Industrials, Financials, Information Technology, Health Care, and Consumer Discretionary.
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.